NEW YORK (Reuters) -CVS Health, UnitedHealth Group and Cigna have asked U.S. Federal Trade Commission chair Lina Khan and commissioners Rebecca Kelly Slaughter and Alvaro Bedoya to disqualify themselves from an FTC lawsuit that has accused the companies of unlawfully inflating insulin prices.

Cigna said that Khan, along with Commissioners Rebecca Kelly Slaughter and Alvaro Bedoya, have made repeated and incorrect prejudgments that show bias against pharmacy-benefit managers.

The healthcare company said Chair Lina Khan, Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro Bedoya through public statements show they have prejudged the matter at hand.

UnitedHealth Group, CVS Health and Cigna all submitted motions Oct. 8 to remove Lina Khan from the Federal Trade Commission’s ongoing antitrust lawsuit. | UnitedHealth, CVS Health and Cigna all view FTC chair Lina Khan as unfair toward PBMs and say she should be removed from the FTC's recently filed antitrust lawsuit.

The FTC has accused units of CVS, Cigna and UnitedHealth of unfair trade practices in how they managed insulin prescriptions.

UnitedHealth Group and CVS Health have petitioned a judge to sideline FTC Chair Lina Khan from the agency’s lawsuit against the largest pharmacy PBMs

The agency has filed an administrative complaint accusing pharmacy benefit managers of artificially inflating the price of insulin.

UnitedHealth Group and CVS Health are asking FTC commissioners to recuse themselves from a case against pharmacy benefit managers due to alleged bias.